MedTrace Logo

World Mosquito Program Noumea - Human Sample Component

NCT03552094 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-02-15

No results posted yet for this study

Summary

The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed. In the absence of specific treatment or vaccine, vector control remains the method of choice to limit their spread. However, the traditional methods of prevention and vector control measure today face their limits: mosquito resistance to insecticides, difficulty of access and destruction of breeding areas... The World Mosquito Program Noumea project is based on the artificial colonization of the mosquito vector Aedes aegypti by the endosymbiotic bacteria Wolbachia, which reduces its ability to transmit arboviruses. The breeding of mosquitoes carrying the bacterium Wolbachia in the laboratories of the Institut Pasteur of New Caledonia requires the use of human blood samples for mosquito gorging.

The objective of the research is to generate, maintain and amplify Aedes aegypti Caledonian lineages carrying the Wolbachia bacteria for the planned insect release program in Noumea.

Conditions

  • Arbovirus Infections

Interventions

OTHER

Blood donations of hemochromatosis or polycythemia patients

Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.

OTHER

Blood donations of healthy donors

Blood samples are from blood donations of healthy donors.

Sponsors & Collaborators

  • Institut Pasteur of New Caledonia

    collaborator UNKNOWN

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Frédéric Touzain · Hospital Center of New Caledonia

  • Myrielle Dupont-Rouzeyrol · Institut Pasteur of New Caledonia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-25
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03552094 on ClinicalTrials.gov